The author wrote that the signals from the sector were unfavorable and that this image was visible throughout Europe. According to the author, the European share of clinical trials had nearly halved in the past 10 to 15 years. As the rapporteur for the European Biotech Act, the author wanted to improve the investment climate with faster procedures. #biotechnologie #klinischeproeven #EuropeseUnie #EU (translated)
